1 ***Klebsiella pneumoniae* mutants resistant to ceftazidime/avibactam plus**
 2 **aztreonam, imipenem/relebactam, meropenem/vaborbactam and**
 3 **cefepime/taniborbactam.**

4
 5 **Naphat Satapoomin^a, Punyawee Dulyayangkul^a, Matthew B. Avison^{a#}**

6
 7 **^aSchool of Cellular & Molecular Medicine, University of Bristol,**
 8 **Bristol. UK**

9
 10 **#Address correspondence to: Matthew B. Avison. bimba@bris.ac.uk**

11
 12
 13 **Running Head: β -lactam/ β -lactamase inhibitor resistance**

14 ABSTRACT

15 Using modified *Klebsiella pneumoniae* clinical isolates, we show that *ramR*
 16 plus *ompK36* mutation together with production of the V239G variant KPC-3
 17 confers resistance to ceftazidime/avibactam plus aztreonam,
 18 imipenem/relebactam and meropenem/vaborbactam, but not
 19 cefepime/taniborbactam. This is because the V239G variant does not generate
 20 collateral β -lactam susceptibility as do many other KPC-3 variants associated
 21 with ceftazidime/avibactam resistance. Additional mutation of *ompK35* and
 22 carriage of a plasmid expressing the OXA-48-like carbapenemase OXA-232
 23 was required to confer cefepime/taniborbactam resistance.

24

25

26 TEXT

27 Aztreonam/avibactam (AZT/AVI) is a β -lactam/ β -lactamase inhibitor combination
 28 currently in clinical trials, which has activity against Enterobacterales producing
 29 metallo-carbapenemases and those with aztreonam-hydrolysing enzymes such as
 30 plasmid-mediated AmpCs (pAmpCs), extended-spectrum β -lactamases (ESBLs) and
 31 the serine carbapenemase KPC. All these enzymes are increasingly carried in
 32 *Klebsiella pneumoniae*, and yet few studies have been performed to consider
 33 mechanisms of AZT/AVI resistance in this species. It was recently reported that
 34 among 8787 Enterobacterales isolates, 17 were AZT-AVI resistant. Of these, three
 35 *Klebsiella* spp, were identified. Production of the pAmpC, DHA-1 plus *acrA* efflux
 36 pump gene overexpression and mutation of *ompK35* or *ompK36* porins were
 37 identified in two resistant isolates. The other produced the ESBL PER-2 and carried
 38 an *ompK35* loss of function mutation (1). In one *in vitro* study, selecting AZT/AVI
 39 resistance identified mutations in the pAmpC, CMY-16 in a *K. pneumoniae* strain (2).
 40 Avibactam is currently in clinical use partnered by ceftazidime (CAZ/AVI) and here,
 41 mutations in KPC are known to confer resistance. However, such mutations tend to
 42 reduce hydrolytic activity to β -lactams other than ceftazidime, including carbapenems
 43 and aztreonam (3-6). Accordingly, it is conceivable that such mutant KPC enzymes
 44 might not confer AZT/AVI resistance.

45 Another recently licenced β -lactam/ β -lactamase inhibitor combination is
 46 imipenem/relebactam (IMI/REL). Unlike AZT/AVI, this does not have efficacy against
 47 isolates producing metallo carbapenemases, but is generally efficacious against
 48 Enterobacterales producing pAmpC, KPC and ESBLs (7). Again, analysis of clinical

49 isolates shows that IMI/REL resistance in *K. pneumoniae* is rare, but resistant
50 isolates have mutations in or reduced expression of *ompK35* and/or *ompK36* porin
51 genes and/or increased *acrA* efflux pump gene expression, alongside ESBL
52 production (8). Similar impacts of porin and efflux pump production on IMI/REL
53 susceptibility have been seen in *in vitro* studies using KPC-producing isolates (9).

54 Given seeming overlaps between AZT/AVI and IMI/REL resistance mechanisms in
55 *K. pneumoniae*, we set out to dissect the mechanisms contributing to resistance to
56 each in *K. pneumoniae* using a bank of clinical isolates and targeted recombinants
57 having fully defined genotypes. **Table 1** reports MICs (determined using CLSI broth
58 microdilution methodology [10,11]) of these combinations against a collection of
59 clinical isolates, which have been previously described (12) and their β -lactam
60 resistance genotypes characterised (13). All isolates, whether producing
61 carbapenemases of classes A (KPC-3), B (NDM-1) or D (OXA-232) were AZT/AVI
62 susceptible, but the NDM-1/OXA-232 producer KP4 was, as expected IMI/REL
63 resistant, as was the OXA-232 producer KP11, though with lower MICs (**Table 1**).

64 Notably, KP4 and KP11 have *ramR* mutations (12), which leads to over production of
65 AcrAB-TolC efflux pump, and reduced production of the OmpK35 porin in *K.*
66 *pneumoniae* (14). Nonetheless, a *ramR* mutant clinical isolate producing KPC-3,
67 KP30, was susceptible to both AZT/AVI and IMI/REL (**Table 1**) so we conclude that
68 modulating production of these permeability-associated proteins is not sufficient to
69 give resistance to either β -lactam/ β -lactamase inhibitor combination in a KPC-3
70 positive background.

71 To investigate the role of *bla*_{KPC-3} mutations known to be associated with CAZ/AVI
72 resistance (15) in AZT/AVI and IMI/REL susceptibility, we took clinical *K.*
73 *pneumoniae* isolate KP21, which is a *ramR* mutant and fully susceptible to AZT and
74 IMI (**Table 1**). We introduced *bla*_{KPC-3} on a plasmid (pKPC-3), either wild-type or
75 following site-directed mutagenesis to create a D178Y or V239G mutations
76 (numbering based on the original KPC-3 sequence nomenclature [16]), previously
77 associated with CAZ/AVI resistance (15). The construction of these plasmids has
78 been reported previously (17). Reduced MICs of AZT and IMI were observed against
79 KP21 carrying the D178Y variant, compared with KP21 carrying wild-type KPC-3
80 (**Table 2**). This phenomenon of reduced spectrum of β-lactamase activity has been
81 described for other *bla*_{KPC-3} mutants associated with CAZ/AVI resistance (3-6).
82 However, in a KP21 background, this reduction in activity was seen to a greater
83 extent for the D178Y mutant, than the V239G variant (**Table 2**). This observation fits
84 with previous reports that *K. pneumoniae* carrying the V239G mutant *bla*_{KPC-3} remain
85 meropenem resistant, while those carrying the D178Y mutant are meropenem
86 susceptible (15, 17). However, AZT/AVI and IMI/REL MICs were not greatly elevated
87 against KP21 carrying pKPC-3 V239G in comparison with KP21 carrying pKPC-3,
88 and all these KP21 recombinants remained AZT/AVI and IMI/REL susceptible (**Table**
89 **2**). We conclude, therefore, that mutating *bla*_{KPC-3} in a way that gives CAZ/AVI
90 resistance is not sufficient to give AZT/AVI or IMI/REL resistance, even in a *ramR*
91 mutant *K. pneumoniae* background.

92 Addition of an OXA-232 (class D carbapenemase) plasmid (pOXA-232, as described
93 in our previous work [17]) to the KP21 recombinant carrying pKPC-3 V239G
94 conferred IMI/REL (but not AZT/AVI) resistance, but this was not seen for KP21

95 recombinants carrying pKPC-3 D178Y or pKPC-3 (**Table 2**). Disruption of the
 96 *ompK36* porin gene in KP21 (as described previously[17]) conferred AZT/AVI and
 97 IMI/REL resistance when the recombinant was carrying pKPC-3 V239G, but not
 98 when it carried pKPC-3 D178Y or pKPC-3. Addition of pOXA-232 to the KP21
 99 *ompK36* recombinants further raised MICs against the pKPC-3 V239G recombinant,
 100 and actually conferred IMI/REL resistance in the recombinant carrying pKPC-3, but
 101 not pKPC-3 D178Y (**Table 2**). Using the *ramR* wild-type isolate KP47 engineered to
 102 have an *ompK36* mutation we confirmed that *ramR* mutation is essential for the
 103 AZT/AVI resistance seen in KP21 *ompK36* pKPC-3 V239G, even following addition
 104 of pOXA-232 (**Table 2**).

105 We therefore conclude that three steps: mutation of *ramR*, mutation of *ompK36* and
 106 carriage of the V239G variant of *bla*_{KPC-3} is sufficient for *K. pneumoniae* to become
 107 resistant to both AZT/AVI and IMI/REL. However, prior to clinical approval of
 108 AZT/AVI, this combination is usually created clinically by adding AZT to CAZ/AVI
 109 therapy. A checkerboard assay confirmed that AZT/AVI and IMI/REL resistant
 110 derivative KP21[*ramR*] *ompK36* pKPC-3 V239G is also resistant to CAZ/AVI plus
 111 AZT, with MICs of CAZ (>32 µg.ml⁻¹) and AZT (16 µg.ml⁻¹) against this recombinant
 112 (**Figure 1**).

113 We have previously shown that this combination of *ramR* and *ompK36* mutation
 114 coupled with acquisition of pKPC-3 V239G also gives resistance to another licenced
 115 β-lactam/β-lactamase inhibitor combination meropenem/vaborbactam (17). Finally,
 116 therefore, we considered the MIC of another combination in late stage clinical trials,
 117 cefepime/taniborbactam (18) against this derivative. Notably, in this *ramR ompK36*

mutant background pKPC-3 D178Y supported lower cefepime MICs than pKPC-3 (Table 3), as seen for the other β -lactams (Table 2) and this was also true for cefepime/taniborbactam (Table 3). But again, the V239G mutant did not suffer from this reduction in cefepime MIC, and the MIC of cefepime/taniborbactam was the same against pKPC-3 and pKPC-3 V239G recombinants of KP21[*ramR*] *ompK36*, being 8 $\mu\text{g.ml}^{-1}$, which is one doubling dilution below the cefepime resistance breakpoint (11) (Table 3). Further addition of pOXA-232 elevated cefepime MICs against the recombinants (Table 3), as expected since OXA enzymes are known to hydrolyse cefepime (19), but the cefepime/taniborbactam MIC remained at $\leq 8 \mu\text{g.ml}^{-1}$ indicating successful inhibition of OXA-232. However, additional insertional inactivation of *ompK35* porin gene (performed as described previously [17]) pushed the cefepime/taniborbactam MIC against KP21[*ramR*] *ompK36* recombinants carrying pOXA-232 and pKPC-3 V239G (but not pKPC-3 D178Y) to 16 $\mu\text{g.ml}^{-1}$, which is classed as cefepime resistant (Table 3).

We conclude, therefore, that whilst three events (*ramR*, *ompK36*, *bla*_{KPC-3} V239G) are sufficient to cause AZT/AVI, CAZ/AVI/AZT, IMI/REL and meropenem/vaborbactam resistance in *K. pneumoniae*, additional events are required to give cefepime/taniborbactam resistance. Furthermore, whilst many *bla*_{KPC-3} mutations leading to CAZ/AVI resistance do come with the collateral effect of increased susceptibility to carbapenems, late generation cephalosporins and AZT, KPC-3 V239G does not suffer from this effect to the same degree. This explains why KPC-3 V239G, rather than KPC-3 D178Y, which does suffer from collateral increased susceptibility is able to confer resistance to multiple β -lactam/ β -lactamase inhibitor combinations, provided their accumulation is slowed. The implication here is

that KPC-3 V239G is inhibited to a lesser extent than KPC-3, rather than having a more ceftazidime focussed hydrolytic spectrum, as does KPC-3 D178Y (20). Accordingly, the emergence of this *bla*_{KPC-3} variant should be watched with caution.

Funding

This work was funded by grant MR/S004769/1 to M.B.A. from the Antimicrobial Resistance Cross Council Initiative supported by the seven United Kingdom research councils and the National Institute for Health Research. N.S. received a postgraduate scholarship from the University of Bristol.

Transparency declaration

The authors declare no conflict of interests.

Figure Legend

Figure 1. Checkerboard assays for CAZ and AZT in the presence of AVI against *K. pneumoniae* KP21[ramR] ompK36 producing KPC-3 V239G.

The image represents duplicate assays for an 8x8 array of wells in a 96-well plate. All wells contained CA-MHB including avibactam ($4 \mu\text{g}.\text{ml}^{-1}$). A serial dilution of aztreonam (AZT, x-axis) and ceftazidime (CAZ, y-axis) was created from $32 \mu\text{g}.\text{ml}^{-1}$ in each plate as recorded. All wells were inoculated with a suspension of bacteria, made as per CLSI microtiter MIC guidelines (10), and the plate was incubated at 37°C for 20 h. Growth was recorded by measuring OD_{600} and growth above background (broth) is recorded as a yellow block; no growth is recorded as a white block. Growth in the red edged block indicates resistance to both AZT and CAZ.

166 **Figure 1**

167

168

Table 1 MICs of aztreonam and imipenem with or without avibactam or relebactam against *K. pneumoniae* clinical isolates

Isolate (relevant genotype)	MIC ($\mu\text{g.ml}^{-1}$)			
	AZT	AZT/AVI	IMI	IMI/REL
KP31 (wild-type)	≤ 0.5	≤ 0.5	≤ 0.5	≤ 0.5
KP21 (<i>ramR</i> TEM-1)	≤ 0.5	≤ 0.5	≤ 0.5	≤ 0.5
KP11 (<i>ramR</i> OXA-232 CTX-M-15 TEM-1)	>128	≤ 0.5	4	4
KP30 (<i>ramR ompK35</i> KPC-3 TEM-1)	>128	1	>128	1
KP4 (<i>ramR</i> NDM-1 OXA-232 CTX-M-15 TEM-1)	>128	≤ 0.5	64	16

Shading indicates resistance based on CLSI breakpoints (11)

Table 2 MICs of aztreonam or imipenem with or without avibactam or relebactam against derivatives of *K. pneumoniae* clinical isolates KP21 and KP47

Isolate	MIC ($\mu\text{g.ml}^{-1}$)			
	AZT	AZT/AVI	IMI	IMI/REL
KP21[<i>ramR</i>] pUBYT	0.5	≤ 0.5	0.5	≤ 0.5
KP21[<i>ramR</i>] pKPC-3	>128	1	64	2
KP21[<i>ramR</i>] pKPC-3 D178Y	1	≤ 0.5	1	0.5
KP21[<i>ramR</i>] pKPC-3 V239G	>128	2	32	2
KP21[<i>ramR</i>] pUBYT pOXA-232	0.5	≤ 0.5	2	1
KP21[<i>ramR</i>] pKPC-3 pOXA-232	>128	2	128	2
KP21[<i>ramR</i>] pKPC-3 D178Y pOXA-232	16	2	2	2
KP21[<i>ramR</i>] pKPC-3 V239G pOXA-232	>128	4	32	8
KP21[<i>ramR</i>] <i>ompK36</i> pUBYT	0.5	1	2	0.5
KP21[<i>ramR</i>] <i>ompK36</i> pKPC-3	>128	2	128	2
KP21[<i>ramR</i>] <i>ompK36</i> pKPC-3 D178Y	8	2	1	0.5
KP21[<i>ramR</i>] <i>ompK36</i> pKPC-3 V239G	>128	16	128	4
KP21[<i>ramR</i>] <i>ompK36</i> pUBYT pOXA-232	1	1	4	2
KP21[<i>ramR</i>] <i>ompK36</i> pKPC-3 pOXA-232	>128	2	>128	32
KP21[<i>ramR</i>] <i>ompK36</i> pKPC-3 D178Y pOXA-232	8	4	8	2
KP21[<i>ramR</i>] <i>ompK36</i> pKPC-3 V239G pOXA-232	>128	16	>128	32
KP47 <i>ompK36</i> pUBYT	0.5	≤ 0.5	0.5	0.5
KP47 <i>ompK36</i> pKPC-3	>128	1	>128	8
KP47 <i>ompK36</i> pKPC-3 D178Y	16	2	1	0.5
KP47 <i>ompK36</i> pKPC-3 V239G	>128	4	>128	16
KP47 <i>ompK36</i> pUBYT pOXA-232	0.5	≤ 0.5	2	1
KP47 <i>ompK36</i> pKPC-3 pOXA-232	>128	1	>128	8
KP47 <i>ompK36</i> pKPC-3 D178Y pOXA-232	16	2	4	2
KP47 <i>ompK36</i> pKPC-3 V239G pOXA-232	>128	4	>128	16

Shading indicates resistance based on CLSI breakpoints (11)

Table 3 MICs of cefepime/taniborbactam against derivatives of *K. pneumoniae*

clinical isolate KP21

Isolate	MIC ($\mu\text{g.ml}^{-1}$)	
	Cefepime	Cefepime/ Taniborbactam
KP21[<i>ramR</i>] <i>ompK36</i> pUBYT	8	1
KP21[<i>ramR</i>] <i>ompK36</i> pKPC-3	>256	8
KP21[<i>ramR</i>] <i>ompK36</i> pKPC-3 D178Y	16	2
KP21[<i>ramR</i>] <i>ompK36</i> pKPC-3 V239G	>256	8
KP21[<i>ramR</i>] <i>ompK36</i> pUBYT pOXA-232	8	1
KP21[<i>ramR</i>] <i>ompK36</i> pKPC-3 pOXA-232	>256	8
KP21[<i>ramR</i>] <i>ompK36</i> pKPC-3 D178Y pOXA-232	64	1
KP21[<i>ramR</i>] <i>ompK36</i> pKPC-3 V239G pOXA-232	>256	8
KP21[<i>ramR</i>] <i>ompK36 ompK35</i> pUBYT	8	1
KP21[<i>ramR</i>] <i>ompK36 ompK35</i> pKPC-3	>256	8
KP21[<i>ramR</i>] <i>ompK36 ompK35</i> pKPC-3 D178Y	16	2
KP21[<i>ramR</i>] <i>ompK36 ompK35</i> pKPC-3 V239G	>256	8
KP21[<i>ramR</i>] <i>ompK36 ompK35</i> pUBYT pOXA-232	8	2
KP21[<i>ramR</i>] <i>ompK36 ompK35</i> pKPC-3 pOXA-232	>256	8
KP21[<i>ramR</i>] <i>ompK36 ompK35</i> pKPC-3 D178Y pOXA-232	64	2
KP21[<i>ramR</i>] <i>ompK36 ompK35</i> pKPC-3 V239G pOXA-232	>256	16

References

1. Mendes RE, Doyle TB, Streit JM, Arhin FF, Sader HS, Castanheira M. 2021. Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019. J Antimicrob Chemother. doi: 10.1093/jac/dkab279. Epub ahead of print.
2. Niu S, Wei J, Zou C, Chavda KD, Lv J, Zhang H, Du H, Tang YW, Pitout JDD, Bonomo RA, Kreiswirth BN, Chen L. 2020. *In vitro* selection of aztreonam/avibactam resistance in dual-carbapenemase-producing *Klebsiella pneumoniae*. J Antimicrob Chemother. 75:559-565.
3. Poirel L, Vuillemin X, Juhas M, Masseron A, Bechtel-Grosch U, Tiziani S, Mancini S, Nordmann P. 2020. KPC-50 Confers Resistance to Ceftazidime-Avibactam Associated with Reduced Carbapenemase Activity. Antimicrob Agents Chemother. 64:e00321-20.
4. Hobson CA, Bonacorsi S, Jacquier H, Choudhury A, Magnan M, Cointe A, Bercot B, Tenaillon O, Birgy A. 2020. KPC Beta-Lactamases Are Permissive to Insertions and Deletions Conferring Substrate Spectrum Modifications and Resistance to Ceftazidime-Avibactam. Antimicrob Agents Chemother. 64:e01175-20.
5. Qin J, Feng Y, Lü X, Zong Z. 2021. KPC-12 with a L169M substitution in the Ω loop has reduced carbapenemase activity. Eur J Clin Microbiol Infect Dis. 40:1761-1766.

- 203 6. Findlay J, Poirel L, Juhas M, Nordmann P. 2021. KPC-Mediated Resistance to
204 Ceftazidime-Avibactam and Collateral Effects in *Klebsiella pneumoniae*.
205 Antimicrob Agents Chemother. 2021 65:e0089021.
- 206 7. Bush K, Bradford PA. 2019. Interplay between β -lactamases and new β -
207 lactamase inhibitors. Nat Rev Microbiol. 17:295-306.
- 208 8. Castanheira M, Doyle TB, Deshpande LM, Mendes RE, Sader HS. 2021. Activity
209 of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam
210 against carbapenemase-negative carbapenem-resistant Enterobacterales
211 isolates from US hospitals. Int J Antimicrob Agents. doi:
212 10.1016/j.ijantimicag.2021.106439. Epub ahead of print.
- 213 9. Balabanian G, Rose M, Manning N, Landman D, Quale J. 2018. Effect of Porins
214 and blaKPC Expression on Activity of Imipenem with Relebactam in *Klebsiella*
215 *pneumoniae*: Can Antibiotic Combinations Overcome Resistance? Microb Drug
216 Resist. 24:877-881.
- 217 10. Clinical and Laboratory Standards Institute. 2015. M07-A10. Methods for dilution
218 antimicrobial susceptibility tests for bacteria that grow aerobically; approved
219 standard, 10th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
- 220 11. Clinical and Laboratory Standards Institute. 2021. M100-S31. Performance
221 standards for antimicrobial susceptibility testing; thirtieth informational
222 supplement. An informational supplement for global application developed
223 through the Clinical and Laboratory Standards Institute consensus process.
224 Clinical and Laboratory Standards Institute, Wayne, PA.
- 225 12. Wan Nur Ismah WAK, Takebayashi Y, Findlay J, Heesom KJ, Jiménez-
226 Castellanos JC, Zhang J, Graham L, Bowker K, Williams OM, MacGowan AP,
227 Avison MB. 2018. Prediction of Fluoroquinolone Susceptibility Directly from

228 Whole-Genome Sequence Data by Using Liquid Chromatography-Tandem Mass
229 Spectrometry To Identify Mutant Genotypes. Antimicrob Agents Chemother.
230 62:e01814-17.

231 13. Takebayashi Y, Wan Nur Ismah WAK, Findlay J, Heesom KJ, Zhang J, Williams
232 OM, MacGowan AP, Avison MB. 2017. Prediction of cephalosporin and
233 carbapenem susceptibility in multi-drug resistant Gram-negative bacteria using
234 liquid chromatography-tandem mass spectrometry. BioRxiv
235 <https://doi.org/10.1101/138594>.

236 14. Jiménez-Castellanos JC, Wan Nur Ismah WAK, Takebayashi Y, Findlay J,
237 Schneiders T, Heesom KJ, Avison MB. 2018. Envelope proteome changes driven
238 by RamA overproduction in *Klebsiella pneumoniae* that enhance acquired β -
239 lactam resistance. J Antimicrob Chemother 73:88-94.

240 15. Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, Pandey R, Doi
241 Y, Kreiswirth BN, Nguyen MH, Clancy CJ. 2017. Emergence of ceftazidime-
242 avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment
243 of carbapenem-resistant *Klebsiella pneumoniae* infections. Antimicrob Agents
244 Chemother 61:e02097-16.

245 16. Woodford N, Tierno PM Jr, Young K, Tysall L, Palepou MF, Ward E, Painter RE,
246 Suber DF, Shungu D, Silver LL, Inglima K, Kornblum J, Livermore DM. 2004.
247 Outbreak of *Klebsiella pneumoniae* producing a new carbapenem-hydrolyzing
248 class A β -lactamase, KPC-3, in a New York Medical Center. Antimicrob Agents
249 Chemother 48:4793-4799.

250 17. Dulyayangkul P, Douglas EJA, Lastovka F, Avison MB. 2020. Resistance to
251 Ceftazidime/Avibactam plus Meropenem/Vaborbactam When Both Are Used

- 252 Together Is Achieved in Four Steps in Metallo- β -Lactamase-Negative *Klebsiella*
253 pneumoniae. Antimicrob Agents Chemother. 64:e00409-20.
- 254 18. Hamrick JC, Docquier JD, Uehara T, Myers CL, Six DA, Chatwin CL, John KJ,
255 Vernacchio SF, Cusick SM, Trout REL, Pozzi C, De Luca F, Benvenuti M,
256 Mangani S, Liu B, Jackson RW, Moeck G, Xerri L, Burns CJ, Pevear DC, Daigle
257 DM. 2020. VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine-
258 and Metallo- β -Lactamases, Restores Activity of Cefepime in Enterobacterales
259 and *Pseudomonas aeruginosa*. Antimicrob Agents Chemother. 64:e01963-19.
- 260 19. Torres E, López-Cerero L, Rodríguez-Martínez JM, Pascual Á. 2016. Reduced
261 Susceptibility to Cefepime in Clinical Isolates of Enterobacteriaceae Producing
262 OXA-1 Beta-Lactamase. Microb Drug Resist. 22:141-6.
- 263 20. Compain F, Arthur M. 2017. Impaired Inhibition by Avibactam and Resistance to
264 the Ceftazidime-Avibactam Combination Due to the D179Y Substitution in the
265 KPC-2 β -Lactamase. Antimicrob Agents Chemother. 61:e00451-17.